SOLIGENIX, INC. — Director's Dealing 2007

Aug 14, 2007

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: DOR BIOPHARMA INC (DORB)
CIK: 0000812796
Period of Report: 2007-08-10

Reporting Person: SCHABER CHRISTOPHER J (Director, Chief Executive Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2007-08-10	Stock Options (right ot buy)	$0.27	A	500000	Acquired	2016-08-28	Common Stock (500000)	Direct
2007-08-10	Stock Options (Right to Buy)	$0.47	A	900000	Acquired	2017-08-09	Common Stock (900000)	Direct

Footnotes

F1: 500,000 stock options were granted on August 10, 2007 as a result of the amendment to the original 2,500,000 options granted on August 29, 2006. This amendment was required because under the 2005 Equity Incentive Plan only 2,000,000 stock options were authorized in a calendar year. This amendment was filed on August 14, 2007 as a Form 3/A (Amendment) of the originally filed Form 3 of September 1, 2006. These stock options will vest 33.3% initially and 8.325% of the remaining balance will vest quarterly over a three year period.

F2: The stock options were granted at an exercise price of $0.47 per share, which is a 68% premium to the Company?s common stock price of $0.28 on August 10, 2007. The stock options, which are for a term of 10 years from the date of grant and subject to earlier termination upon the occurrence of certain events related to termination of employment, vest at the rate of 25% immediately and 25% per year for 3 years.